Article Information
History
- January 3, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Jinyan Liu1,*,
- Abishek Chandrashekar1,*,
- Daniel Sellers1,*,
- Julia Barrett1,
- Michelle Lifton1,
- Katherine McMahan1,
- Michaela Sciacca1,
- Haley VanWyk1,
- Cindy Wu1,
- Jingyou Yu1,
- Ai-ris Y. Collier1 and
- Dan H. Barouch1,2,**
- 1Beth Israel Deaconess Medical Center, Boston, MA, USA
- 2Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
- ↵**Corresponding author: Dan H. Barouch, M.D., Ph.D., Center for Virology and Vaccine Research, 330 Brookline Avenue, E/CLS-1043, Boston, MA 02115; Telephone: 617-735-4485; Fax: 617-735-4566; Email: dbarouch{at}bidmc.harvard.edu
Posted January 03, 2022.
Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant
